ArticleDiscover oncology2025
Network pharmacology and experimental study on the inhibition of glycolysis by amentoflavone in pancreatic cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundsPancreatic cancer is one of the most common malignancies in the gastrointestinal system, notorious for its high malignancy and low survival rate. Amentoflavone (AMF), an ingredient in various Traditional Chinese Medicines (TCM), possesses anticancer properties. However, the underlying mechanisms of its action remain unclear.
methodsInitially, through the application of network pharmacology and molecular docking methodologies, we elucidated the putative core targets and signaling pathways underlying the antineoplastic potential of amentoflavone. Subsequently, we corroborated the therapeutic efficacy and underlying mechanisms of amentoflavone within both in vitro pancreatic cancer cell models and in vivo animal models.
resultsThe key targets of amentoflavone were identified as SRC, AKT1, PI3KR1, VEGFA, ESR1, EGFR, and AR, among others. The mechanisms of action may involve protein phosphorylation, autophosphorylation, and positive regulation of apoptosis. KEGG analysis enrichment indicated that pathways such as Cancer, Estrogen Signaling, and PI3K/AKT/mTOR played a significant role. Molecular docking experiments demonstrated that amentoflavone showed good docking activity with the main target proteins. In vitro and in vivo experiments showed that amentoflavone effectively induced apoptosis in BxPC3 cells, inhibited cell migration, caused cell cycle arrest at the S phase, and regulated glycolysis in BxPC3 cells by inhibiting the PI3K/AKT/mTOR pathway. Additionally, amentoflavone effectively inhibited the growth and glycolytic process of pancreatic cancer xenografts in mice.
conclusionsOur study elucidates that amentoflavone inhibits pancreatic cancer development by regulating the glycolysis process through the suppression of the PI3K/AKT/mTOR pathway, thereby providing novel targets and therapeutic strategies for the treatment of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.